Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.
Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.
According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.
Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.
Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range".
Eurovet Animal Health Ltd has entered the UK veterinary pharmaceuticals market with a portfolio of products including a levothyroxine tablet for the treatment of canine hypothyroidism, injectables for cattle and pigs, a xylazine injection for use in cattle, horses, dogs & cats and a corticosteroid for use in horses, cattle, pigs, cats and dogs.
Eurovet Animal Health is a subsidiary of Dutch company, AUV, which was established in 1969 as a cooperative by 100 veterinary surgeons, and is now jointly owned by 2000 vets. The company says this gives it a unique perspective on the products that veterinary surgeons really need and want. And whilst Eurovet Animal Health is still relatively small in the UK, the parent company Eurovet Animal Health BV owns state-of-the-art manufacturing facilities and provides access to international expertise, support and resources.
Eurovet Animal Health Ltd will be offering Eurovet products previously distributed by partner companies in the UK, so vets can expect to see brands they know and trust, as well as new brands. Existing products will be available from veterinary wholesalers and include:
Further information about Eurovet's range of products is available from Eurovet Animal Health, Compass House, Chivers Way, Histon, Cambridge, CB24 9AD Tel: 01223 257933 E-mail office@eurovet-ah.co.uk http://www.eurovet-ah.co.uk/
Alstoe Animal Health has introduced a new, palatable joint nutrient supplement for horses.
According to the company, the benefits of feeding equine joint nutrient supplements to assist with maintaining mobility and supporting health joint function has been well documented, but until now, their flavours have often had to be disguised by mixing them into the feed in an attempt to ensure compliance.
Easeflex Equine palatable pellets include alfalfa, an equine favourite which has been used in the USA for some time, and shown to be readily accepted by horses, without the need to mix with the feed.
Alstoe says Easeflex Equine contains high levels of glucosamine hydrochloride and chondroitin sulphate, which are important in the production of glycosaminoglycans, and which have chondroprotective properties that aid in the natural renewal of cartilaginous tissue. Easeflex Equine palatable pellets also include MSM (methyl-sulphonyl-methane), a source of bioavailable sulphur, a key component of connective tissue and important in the synthesis of articular cartilage. Antioxidants are also present to help prevent damage by free radicals, as well as the essential trace minerals, copper, zinc and manganese.
Easeflex Equine palatable pellets can be fed to horses, ponies and donkeys of any age. The company recommends initial daily feeding of a double loading quantity for the first four to six weeks, thereafter reducing to a maintenance level or as directed by the veterinary surgeon. The amount of pellets to be fed depends on the weight of the animal, one small scoop containing 28g of pellets can be a daily dose for a horse of up to 450kg. Easeflex Equine palatable pellets are available in 1.7kg and 4.54kg tubs.
ECM, a French manufacturer of ultrasound devices, has launched Exago, a new mobile veterinary ultrasound device which the company says is particularly suited for use with horses and pets.
ECM says the main features of the new device are:
For more information, visit: http://www.agroscan.com/
From 1st March vets can sign up to be alerted to all recorded equine influenza cases in the UK, thanks to a new service from the Animal Health Trust (AHT) and Merial Animal Health.
Tell Tail is the UK's first equine influenza (EI) text alert service exclusively for equine vets, set up to provide practices and their clients with what could be invaluable information in the face of a potential outbreak.
Dr Emma Batson from Merial said: "Vets will be notified of an EI outbreak within 48 hours of confirmed diagnosis. Not only will this allow them to alert their clients, but we believe that it will also help to encourage horse owners to become more compliant with vaccination schedules.
"Currently it is estimated that only a third of the UK horse population is vaccinated for EI. This situation is not only a potential welfare issue, but it also provides practices with a significant opportunity to increase the number of horses protected against EI, resulting in a win-win situation for all."
Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT, believes the text alert service will also help improve awareness and knowledge of EI, and he hopes all equine vets will sign up for the scheme. He said: "We believe that the launch of the alert service for vets marks an important step in the quest to help minimise the risk of an EI outbreak in the UK.
"EI doesn't have a carrier state, which means that it never goes away and re-emerges, instead it circulates continuously. So without continued surveillance we could easily lose track of it.
"We hope that as well as allowing practices to track and respond to outbreaks in their area, the alerts will also encourage vets to send in samples from animals with cold and flu-like symptoms. This is a free service which in turn provides us with more information to circulate within the industry, allowing everyone to be more effective at managing the disease.
"Vaccination is our best defence against EI, but to remain effective the World Organisation for Animal Health (OIE) Expert Surveillance Panel, needs to make any update recommendations based on the latest position in the field. And this information can only be gathered via effective surveillance."
Dr Batson agrees and hopes that the combination of the Tell Tail text alert service and surveillance scheme will help to reduce the risk of an outbreak occurring in the UK. She said: "In the UK we continue to see regular confirmed outbreaks of EI, so we can never afford to become complacent about the risks.
"You only have to look at the relatively recent major outbreaks in Australia, South Africa, India and China, to see the devastating effects which can ripple throughout equine industries, both in financial as well as welfare terms."
Tell Tail is a free service. To register your interest, text your name, practice and postcode to 07797 801863. Alternatively, visit http://www.merial.com/ and click on the Tell Tail link, or speak to your Merial territory manager.
The Veterinary Wound Healing Association (VWHA) has become the third veterinary association to make a new home on VetSurgeon.org.
VWHA President Jacintha Wilmink said: "We're very excited about joining VetSurgeon.org and how it will allow our members to connect with each other and share information quicker and more easily than ever before".
In common with the other associations, the VWHA is making its content available for all VetSurgeon members to access, however only VWHA members can submit cases to its section for discussion, or participate in the VWHA forum. Jacintha added: "We hope that the cases and discussions in our section of the site will be of value to all practitioners, and that many more of you will want to join the association and participate".
Information about the benefits of joining the VWHA is available here.
The National Association of Veterinary Physiotherapists (NAVP) is calling for the Royal College of Veterinary Surgeons (RCVS) to establish an independent register of veterinary physiotherapy practitioners. According to the Association, such a register would eliminate individuals practicing without proper training and qualifications and raise the standard of veterinary physiotherapy by providing a disciplinary role.
NAVP President and leading veterinary anatomist Dr Sue Kempson is heading the NAVP campaign for the establishment of an independent register. In a letter to the President of the RCVS, Dr Kempson said: "Recognition by the veterinary profession of the role of physiotherapy in post-operative rehabilitation and in supporting both companion and performance animals is growing. However, we do believe that referring veterinary surgeons are increasingly faced with a dilemma caused by the wide differential between qualifications offered by the various organisations representing practitioners in areas such as physiotherapy. There is an urgent need for a distinction to be made between these different types of qualification. To this end, there should be a clearly defined independent register of practitioners with appropriately validated qualifications which are clearly understood by the veterinary profession."
In partnership with Harper Adams University College, the NAVP has introduced a fully-validated post-graduate course in veterinary physiotherapy which offers a choice of Post-Graduate Diploma or Masters Degree. Only one other professional body, the Association of Chartered Physiotherapists in Animal Therapy (ACPAT) currently offers a similar qualification at this level.
Dr Kempson said: "The establishment of a register of physiotherapists would greatly assist vets and their clients to make informed decisions on their choice of therapist. It would eliminate those individuals without proper training and qualifications and help raise the standard of veterinary physiotherapy by providing a disciplinary role. At present there are no sanctions on those people practicing without the necessary qualifications or those whose work is sub-standard or who are guilty of professional misconduct.
"We do not believe that such a register should rest with any individual professional body or be affiliated to specific educational courses. To have authority, it requires independence and a register held under the auspices of the Royal College of Veterinary Surgeons would carry the credibility that the veterinary profession requires."
A DNA test which will save foals from unnecessary pain and suffering, and ultimately death, has been launched by the Animal Health Trust.
Foal Immunodeficiency Syndrome (FIS), a genetic disorder which is known to affect Fell and Dales ponies, causes foals to become anaemic and prone to opportunistic infections. Any foal born with the syndrome will not survive.
The new diagnostic DNA test, which costs £40, is the result of ten years of research by the Animal Health Trust (AHT) and the University of Liverpool. The test will not only identify foals which have the fatal condition but will highlight adult ponies who are carriers of the genetic trait which causes the syndrome. Affected foals will be prevented by avoiding covering a carrier mare with a carrier stallion.
Owners and breeders who wish to find out the genetic status of their ponies can arrange for a simple pulled mane or tail hair sample to be taken by a vet and submitted to the AHT. The Fell Pony or Dales Pony Societies will supply sample bags for submission on request. A fast-track system to identify foals suffering with the condition will report results within three working days.
The team that developed the DNA test was led by the AHT's Dr June Swinburne and Professor Stuart Carter of the University of Liverpool with research student Laura Fox-Clipsham. They believe that by using the test, owners and breeders will eventually be able to eradicate this awful condition.
Dr. June Swinburne, said: "The DNA test gives owners and breeders the power to overcome this devastating illness. It enables them to make informed decisions about which ponies to breed. We have already had samples submitted by HM The Queen from her own breeding stock of Fell ponies. I'd urge any breeders of Fell or Dales ponies to submit samples in order to arm themselves with the facts they need to prevent the birth of affected foals and thereby avoid this distressing condition."
Professor Carter, said: "The research, and ultimately the DNA test, has only been possible thanks to funding from The Horse Trust and the support of the Fell Pony Society and the Dales Pony Society who have supplied DNA samples. We consider that the efforts of all involved in enabling this research have lead to a major advance in animal welfare."
For more information on testing, contact the Fell or Dales Pony Societies. Alternatively visit the AHT website http://www.aht.org.uk/genetics_fis.html or email FIStesting@aht.org.uk
Practices will be able to offer customers increased support for their worming programmes in 2010, as part of a new initiative from Eqvalan® manufacturer, Merial.
Eqvalan product manager Claire Edmunds said: "The SMART worming campaign is designed to encourage owners to Simply Monitor, Assess Risk and, if necessary, Treat with the most appropriate wormer.
"We know that worming can be confusing for horse owners, so the SMART approach is designed to help them manage their worming programmes more easily, whilst also ensuring that wormers are used in a way that may help prevent the development of resistance.
Practices purchasing Eqvalan Duo during February and March can get 4 tubes free when they purchase 20. In addition, to kick start the SMART campaign for each order on the above offer, Merial will supply 20 free Worm Egg Count vouchers worth £10/€10 each. For those practices with their own testing facilities, the company is also offering promotional support to help encourage increased uptake and client buy-in.
Claire added: "As well as continuing with the successful free worm egg count campaign available for practices during February and March, owners will also have access to a personalised on-line planner, as well as text and email alerts.
"The campaign is being supported with new point of sale material and a prominent consumer advertising campaign. In addition we also have an extensive VN SQP CPD training programme planned for 2010.
"With the consensus of expert opinion on the future of worming firmly behind the use of targeted programmes incorporating worm egg counts, there has never been a more important time to get closer to clients and help them with their worming strategies."
If you would like further information, please contact your local territory manager or call the Merial Customer Support Centre on 0845 601 4236.
Defra has confirmed that equine infectious anaemia (EIA) has been detected in two horses in Wiltshire following importation from Romania via Belgium.
The premises is currently under restriction and the two infected horses will be humanely destroyed in line with existing regulations. The other horses on the premises will be subject to epidemiological investigation in the coming weeks. A further two horses have also been under investigation and test results have proved negative.
The animals arrived in a group of 10 horses, nine of which originated from Romania and one from Belgium. The nine Romanian horses were tested for EIA as part of routine post-import testing. Seven horses all tested negative. The horse that originated in Belgium is due to be tested shortly.
Chief Veterinary Officer, Nigel Gibbens said: "This is the first case of equine infectious anaemia infected animals being imported into Great Britain since 1976 and shows the success of our post import testing regime. These were apparently healthy horses carrying a notifiable disease that we are keen to keep out of Great Britain. After considering the risk I have decided to take appropriate action and humanely destroy these two horses that tested positive."
Intervet/Schering-Plough Animal Health has reported that since launch, its diagnostic service RespCheck has identified infectious diseases in 15 per cent of all animals checked under the scheme.
Offered to qualifying practices for no charge and implemented by the Animal Health Trust (AHT), Intervet/Schering Plough set up RespCheck to help identify the cause of infectious respiratory problems in horses.
The RespCheck kit, which has been used to swab more than 700 horses since launch, consists of naso pharyngeal swabs, enabling two horses per yard or outbreak to be swabbed for a variety of diseases. These include equine influenza, equine herpesvirus, Streptococcus equi (strangles), pasteurella, rhinovirus and Streptococcus zooepidemicus. The swabs are sent to the AHT for analysis and the results returned direct to the vet.
John Dickerson from Chine House Equine Hospital in Leicestershire said: "The service is fantastic, made all the better by being completely free of charge! The benefits are two-fold. From the clinical perspective it means we can discount or treat potential infections in a more timely fashion; for instance, we use RespCheck to screen for any suspected infectious respiratory disease cases which enables us to deal with the problem, through quarantine and strict hygiene measures, helping to prevent the spread of the disease.
The other benefit is to our practice reputation and the standard of service we can offer. It's great to be able to provide owners with peace of mind without it costing more than our call out fee. By the time an owner calls the vet they are usually stressed and worried about their horses symptoms and need some reassurance, which is exactly what RespCheck gives them. We are confident that providing a diagnostic service that is completely free and that puts an owners mind at rest regarding the risk of an infection can only be a good thing for our practice reputation and customer care.
Last year, the service proved its worth when the screening of a recently imported horse showed the animal had equine influenza. I believe that had RespCheck not been employed, we would have had an outbreak in that particular yard."
Practices interested in knowing more about RespCheck should contact their local Intervet/Schering-Plough Veterinary Business Manager or phone the company's Veterinary Support Group on 01908 685685.
Ridgeway Research Ltd has a surplus supply of short-dated Target IgG kits on special offer.
The kits are to test for passive transfer to foals via colostrum. Each kit contains 20 tests and normally costs £74. They have been reduced to £20 to clear. The use by date is end February 2010.
If you are interested, please email jo@ridgewayresearch.co.uk, or ring 01594 530809 for further information.
A research project funded by equine charity The Horse Trust has succeeded in killing equine sarcoid cells in vitro by silencing a gene in the virus that causes sarcoids. The researchers are now hoping to obtain funding for clinical trials using the new technique, which could result in a more effective, non-toxic treatment for sarcoids.
Sarcoids are skin tumors caused by infection with the Bovine Papillomavirus (BPV). They are the most common type of tumour found in horses - the estimated prevalence in the UK is 6-7%. Although the disease is rarely life threatening, many horses with sarcoids are euthanased because the condition is untreatable or because the horse is unsellable. Currently there is no universally effective treatment for sarcoids and if treatment fails the sarcoids will often come back worse.
However, research that was given funding by The Horse Trust offers a potential ray of hope for owners of horses affected by sarcoids. The research was published in Virus Research journal earlier this year.
The research, which was led by Professor Lubna Nasir of the University of Glasgow, found that by inhibiting the activity of a particular viral protein within sarcoid cells, the amount of viral DNA in the cells reduced. This led to a reduction in the growth of the sarcoid cells and caused the cell to die by Programmed cell-death (PCD). The researchers believe that PCD occurs because the sarcoid cells become reliant on the virus.
Professor Nasir said: "This could potentially be a major breakthrough in the treatment of sarcoids. We are now seeking funding to use this technique in clinical trials on horses that have sarcoids."
The research team inhibited the activity of a viral protein called E2, which is needed by BPV to replicate. They used a novel approach termed 'gene silencing' to suppress the activity of the gene that codes the E2 protein. The research was carried out in vitro on fibroblast cells, which had been cultured from sarcoid tissue removed from animals during surgery.
As this research was carried out in vitro, the researchers will now need to see if they can replicate the results in vivo, by developing a way of targeting the sarcoid cells in horses.
"One of the challenges with gene silencing is administering it within clinical setting - as you need to get molecules into every cell. As sarcoids are on the surface of a horse, we think administration should be relatively easy - potentially by injecting or applying a cream to the sarcoid," said Professor Nasir. "If we are able to successfully develop this technique it would be a non-toxic and easy to administer treatment for horses affected by this distressing condition."
Nasir's research could also have an impact on the treatment of lesions in cattle, which are also caused by BPV. Around 50% of cattle in the UK are estimated to have lesions. It may also help with the treatment of Human Papillomavirus (HPV) infections in humans. HPV, which is similar to BPV, can lead to various cancers in humans including cervical and vaginal cancer.
Paul Jepson, Chief Executive and Veterinary Director of The Horse Trust said: "We are really excited that the research we have funded could lead to a major breakthrough in the treatment of sarcoids."
Janssen Animal Health has announced that it has acquired the distribution rights for a range of sedatives and anaesthetics for small and large animals, including Dexdomitor, Domitor and Antisedan.
Janssen aquired the marketing and distribution rights, which were previously held by Pfizer Inc, from Orion Corporation.
Dr. Enno Gottschalk , Janssen's European Director Marketing and Sales said: "This acquisition of distribution rights results in the perfect combination of proven and effective products with the outstanding service and technical selling capabilities of Janssen Animal Health. The products include the sedative Dexdomitor and Domitor, as well as the antagonist Antisedan. Among large animals, predominantly horses, the sedative injection Domosedan is now on offer as part of the Janssen Animal Health portfolio."
Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
Veterinary practices are being encouraged to enter the annual Veterinary Marketing Association's (VMA) awards, which now include a practice-only category.
The annual VMA awards are intended to recognise excellence in all aspects of veterinary and animal health marketing. The Practice Marketing Award, sponsored by Pfizer, is awarded to the companion or production animal practice that demonstrates the most initiative and innovation in the marketing of its products and/or services to end users. This can involve the use of any form of activity, including advertising, websites, direct mail and media relations.
Last year's winner of this award was Kessock Equine Vets from Aberdeen, who travelled down to London to receive their award at a presentation lunch. The 2009 awards presentation ceremony takes place on Friday, 19th March at the Old Brewery in Chiswell Street, London. The meeting also presents a very good opportunity for vets to meet representatives from all the major animal health companies.
Tickets for the event cost £115+VAT for VMA/VMPA members (£150+VAT for non-members). The price includes a three-course meal (prepared by a two-star Michelin chef) with wine, a champagne reception and entertainment by a top comedian.
Further information on the awards is available on the Veterinary Marketing Association's website - http://www.vma.org.uk/. Closing date for entries is 5th February 2010.
Gil Riley of the Pool House Veterinary Hospital in Lichfield, Staffordshire has won the annual Petplan Equine Vet of the Year Award.
The Award was announced at the 21st annual Animal Health Trust (AHT) Equestrian Awards gala dinner held at the Lancaster Hotel in London last Thursday.
Horse owners from all over the UK nominated vets who had gone above and beyond the call of duty. A short list of three finalists was then drawn up and the winner selected by an independent panel consisting of: Peter Webbon AHT Chief Executive and Equine Vet, Alison Bridge Editor-in-Chief of Horse & Rider Magazine, Chris House President of the British Equine Veterinary Association (BEVA) and Jo Whitaker Marketing Development Manager for Petplan.
Peter Webbon of the AHT said "We received a record number of nominations this year and the standards were incredibly high. However, Gil was nominated by over 100 clients and we felt he was truly deserving of this award."
Alison Andrew, Marketing Manager for Petplan said: "This award recognises the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners."
Gil joined the Pool House Veterinary Group and Equine clinic practice to expand his equine skills after working in a mainly agricultural practice in Wales and is jointly responsible for the Equine part of the Practice. He has subsequently been awarded the Royal College of Veterinary Surgeons Certificate in Equine Practice and he is particularly interested in lameness and laminitis. He also recently acted as British Team Vet at the International Driving Trials in Germany.
Gil said: "Everyday I feel like I'm pulling the greatest trick in that I get paid for doing what I love. To receive further recognition with this award almost feels greedy. I'm tremendously flattered and indebted to all my clients who nominated me."
In his acceptance speech Gil praised his team for their dedication and support without whom, he said this would not have been possible. Special thanks went to his proud wife Emma on the evening of their fifth wedding anniversary.
The Animal Health Trust Equestrian awards are designed to recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. Since the Petplan Charitable Trust was founded in 1994 it has raised over £5million, almost £500,000 of which has been donated to the AHT to fund research and development.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
Petplan, the pet insurance provider has been selected as a Which? Best Buy. The independent consumer guide selected Petplan's 'Covered For Life' policy that covers animals for accidents and illnesses, including reoccurring conditions, such as diabetes and glaucoma, year after year, as long as the policy is renewed annually.
Alison Andrew, Petplan's Marketing Manager said: "The Which? report is crucial to being acknowledged as a worthy pet insurance provider. We feel being selected as a Which? Best Buy reflects how we treat our customers by offering excellent customer service, paying claims quickly, discounts on pet products and regular information about pet care through our magazine PetPeople."
Petplan provides insurance cover for dogs, cats, rabbits and horses and is the largest provider of animal health insurance in the world.
The Disciplinary Committee of the RCVS has approved an application for restoration to the Register from an Oxfordshire veterinary surgeon who had been struck off for false certification.
In November 2007, the Committee decided that Mr John Williams, of the Avonvale Veterinary Practice in Ratley, near Banbury, should have his name removed from the RCVS Register, having found him guilty of disgraceful professional conduct. Mr Williams had admitted signing export health certificates for three horses in October 2006 to state that they had received negative test results for the contagious equine metritis organism, before these results were actually available.
At the time, Mr Williams was working in his capacity as an Official Veterinarian (OV) for DEFRA and he had previously been suspended from his official duties on three separate occasions, on the basis of export certification irregularities. It was accepted that Mr Williams had not been dishonest, but his approach to certification was described by the Disciplinary Committee as "either irresponsible or cavalier or both".
In December 2007, Mr Williams appealed against this decision to the Privy Council but this was dismissed at a Hearing the following June. He was then removed from the Register in July 2008.
When the Committee met on Monday to consider Mr Williams' application, they heard oral and written supporting evidence from veterinary surgeons and equine clients, and oral evidence from Mr Williams himself. The Committee was satisfied that Mr Williams accepted its previous findings and fully understood their seriousness. He described his removal from the Register as a "salutary experience" which had been highly significant for him and his family, both financially and emotionally.
The Committee stated: "Although the decision of the Committee to remove [Mr Williams] from the Register sent a clear message to the profession of the importance of certification, it should be emphasised that his removal was the consequence of his actions in signing certificates which he could not verify. This followed three previous occasions on which he had similarly signed certificates when he should not have done so."
However, the Committee was satisfied that Mr Williams would not in future sign certificates when he should not do so, even under severe client pressure. It was impressed with the continuing professional development he had undertaken whilst off the Register and noted that no questions had been raised over his conduct during this time.
It concluded that Mr Williams fully understood the importance of accurate certification and that restoring his name to the Register therefore posed no risk to animal welfare. Neither the public nor the profession would benefit from Mr Williams staying off the Register for a further period.
Alison Bruce, Disciplinary Committee Chairman, said: "We would like to make it clear that we always find it distressing to remove clinically competent veterinary surgeons from the Register because of an irresponsible and cavalier attitude towards certification. This would not be necessary if veterinary surgeons were to follow the Twelve Principles of Certification annexed to the RCVS Guide to Professional Conduct."
The Committee then approved Mr Williams' application and directed that his name should be restored to the Register.
An international group of scientists has published new results that herald a breakthrough in finding a vaccine against the most commonly diagnosed infectious disease of horses, strangles.
UK experts from the Animal Health Trust collaborated with scientists from the Swedish University of Agricultural Sciences (SLU), the Karonlinska Institutet Medical University and Intervacc AB, on the project - the results of which could benefit humans as well as animals.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "We have been working towards developing a vaccine for 7 years, and finally it seems as if all the hard work is paying off. We've already developed better ways of diagnosing exposure to the infection, and now, with the success of creating a safe and effective vaccine, it looks as if we're finally bringing together the tools necessary to eradicate this terrible disease."
The vaccine consists of seven different Streptococcus proteins and results from early tests published in PLoS Pathogens have been incredibly positive showing a high level of protection and no side effects. It is hoped that the strangles vaccine could be commercially available in the near future.
Streptococcus equi, the bacterium that causes strangles, shares 80 per cent identity with Streptococcus pyogenes - the leading cause of bacterial pharyngitis, tonsillitis and rheumatic fever in humans, which kills thousands of people each year. Scientists hope that the knowledge gained through developing the strangles vaccine will also help in developing vaccines to combat these human conditions.
Research leader, Professor Bengt Guss of SLU, said: "This is a most exciting project, where research is generating new applications and knowledge that can be used to develop vaccines against these important bacteria. This is particularly important considering the increased number of infectious diseases caused by antibiotic-resistant bacteria."
The vaccine development work was only made possible thanks to information from the Streptococcus equi genome sequencing project funded by The Horse Trust.
The Horse Trust's Chief Executive Brigadier Paul Jepson, said: "We are absolutely delighted that by pulling apart the genome of this plague of the horse world scientists have generated a truly safe and effective strangles vaccine. That this work could also benefit other animal and human health is beyond our wildest hopes."
Full text of the research findings can be found in PLoS Pathogens online at http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000584
A new equine parasite supplement to the online peer-reviewed publication Parasites and Vectors has been published by Fort Dodge.
Entitled "Equine parasites: diagnosis and control - a current perspective," it contains papers on a range of topics including a major European resistance study into key anthelmintic molecules. It is authored by equine parasitology experts and opinion leaders from around the world and was first published in September 2009. It is freely available at http://www.parasitesandvectors.com/
The National Office of Animal Health (NOAH) has launched a new 'Use Medicines Responsibly' campaign.
The main thrust of the campaign is an initiative by NOAH to encourage pharmaceutical companies to add: 'Use Medicines Responsibly' as a strapline to their own advertising campaigns, with a link to the NOAH information resource for prescribers and users of animal medicines: www.noah.co.uk/responsible.
Speaking at the NOAH annual members' conference in Northampton, NOAH chief executive Phil Sketchley said: "NOAH believes responsible promotion of animal medicines to be an important link in the chain towards responsible use. Companies' promotional material can educate prescribers and users of animal medicines to the benefit of their animals' health and welfare.
"We believe this new advice resource, with the reminder on advertisements, will help."
VetHelpDirect.com, a website which helps pet owners decide how urgently their pet needs veterinary attention, has been relaunched with new content for donkey, reptile and bird owners.
Founded by VetSurgeon member Susie Samuel MRCVS in 2006, the site allows pet owners to look up the symptoms their animal is displaying. When the owner answers a series of simple, step-by-step questions, the site then generates a priority rating from "Self care - treatment at home" to "Urgent - you need to contact your vet immediately", coupled with specific first aid advice. It's a sort of home triage system.
VetHelpDirect was designed by vets and all of the content is by vets. The site covers dogs, cats, rabbits, horses and now donkeys, reptiles and birds. I see that the world-renowned avian vet (and all-round good bloke) Neil Forbes FRCVS and his team at Great Western Referrals, together with Dr Karen Rickards, head vet at the Donkey Sanctuary have helped create the new areas of the website, so the information it contains will certainly be of the highest standard.
In fact, the whole site is impressively well-designed and simple to use, an opinion obviously echoed by the readers of WebUser magazine, who gave it 5/5 stars last May, beating Jamie Oliver's website.
Cleverly, the triage system on VetHelpDirect ties in with a directory of veterinary practices, so if immediate care is the answer and the owner doesn't have a vet already, help is at hand. Veterinary practices can pay to have an enhanced listing in the directory.
For a fee, VetHelpDirect can also embed the triage system into your own practice website. That seems like a good way of adding additonal, interesting and interactive content to a website. The interesting question is how much money it will save the practice by eliminating unecessary calls from pet owners who don't really need to talk to a vet.
Equally, though, the site may have an important role to play in telling owners when they SHOULD get to the vet quickly. A recent success story was that of 'Bucket', a 5 year old cat from Nottingham. Bucket was fortunate to live after his owner Sarah Rennoldson logged on to Vet Help Direct.com after he displayed odd behaviour. Acting on the advice displayed on the site her owner immediately contacted her local vet Jaqui Gilmour MRCVS at Bill Bowlers Vets. Bucket was diagnosed with a blocked bladder, which was quickly operated on. Jaqui said: ' If Sarah hadn't brought Bucket in so quickly, he could have gone into renal failure and could have developed metabolic disturbances. He would have been really, really sore, and left untreated a blocked bladder can cause death.'
For more information, 'Start a Conversation' with Susie Samuel MRCVS
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.